Efficacy evaluation of Bauhinia variegata L. stem bark powder as adjunct therapy in chronic Staphylococcus aureus mastitis in goat
Jeevan Ranjan Dash1, Tapas Kumar Sar1, Indranil Samanta2, Subodh Pal1, Madhuchhanda Khan1, Nimai Chand Patra3, Uttam Sarkar4, Asit Kumar Maji5, Tapan Kumar Mandal1
1 Department of Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India
2 Department of Veterinary Microbiology, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India
3 Department of Veterinary Pathology, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India
4 Department of Animal Genetics and Breeding, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India
5 Department of Veterinary Surgery and Radiology, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal, India
|Date of Submission||05-Feb-2014|
|Date of Acceptance||24-Feb-2014|
|Date of Web Publication||30-Aug-2014|
Tapas Kumar Sar
Department of Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Objective: The objective was to study the effect of Bauhinia variegata L. stem bark powder as adjunct therapy in chronic Staphylococcus aureus mastitis in goat. Materials and Methods: Mastitis was induced by intracisternal inoculation of coagulase positive S. aureus (J638) at the concentration of 2000 colony forming units. Group I animals were treated with repeated dose of ceftriaxone at 20 mg/kg intravenously, and Group II animals were treated with once daily oral administration of B. variegata L. stem bark powder at 6 g/kg for 7 days followed by maintenance dose at 3 g/kg for next 7 days along with repeated dose of the antibiotic at 20 mg/kg intravenously at 4 days interval. Results: No significant improvement in the clinical condition of the udder was noticed in the group treated with repeated dose of ceftriaxone alone. However, in the group treated with B. variegata L. stem bark powder along with repeated dose of ceftriaxone, no S. aureus colony was seen at 96 h and onwards in milk samples with a marked decrease in somatic cell count and milk alkaline phosphatase activity and increased lactoperoxidase activity. Further, plasma and milk concentration of ceftriaxone/ceftizoxime was increased, which indicated antibacterial, bioenhancing and antiinflammatory properties of the bark powder. The Group II animals also exhibited marked reduction in polymorphonuclear cells and fibrous tissue indicating antifibrotic property of B. variegata L. Conclusion: B. variegata L. stem bark powder can be considered as an effective adjunct therapy to intravenous ceftriaxone in S. aureus chronic mastitis in goat.
Keywords: Bauhinia variegata L. ceftriaxone, chronic mastitis, goat, Staphylococcus aureus
|How to cite this article:|
Dash JR, Sar TK, Samanta I, Pal S, Khan M, Patra NC, Sarkar U, Maji AK, Mandal TK. Efficacy evaluation of Bauhinia variegata L. stem bark powder as adjunct therapy in chronic Staphylococcus aureus mastitis in goat. Phcog Mag 2014;10, Suppl S3:512-8
|How to cite this URL:|
Dash JR, Sar TK, Samanta I, Pal S, Khan M, Patra NC, Sarkar U, Maji AK, Mandal TK. Efficacy evaluation of Bauhinia variegata L. stem bark powder as adjunct therapy in chronic Staphylococcus aureus mastitis in goat. Phcog Mag [serial online] 2014 [cited 2021 May 17];10, Suppl S3:512-8. Available from: http://www.phcog.com/text.asp?2014/10/39/512/139786
| Introduction|| |
Mastitis is a major problem in goats. The predominant bacterial species responsible for mastitis in dairy goats is Staphylococcus aureus and its prevalence in dairy goat herds varied widely from 7% to 40%.  Use of antibiotic is commonly practiced in mastitis therapy.  Selection of the antimicrobial agent and maintenance of adequate concentration of the drug at the site of infection are the most relevant problems in antibiotic therapy of mastitis. It has been reported earlier that an active metabolite of ceftriaxone that is, ceftizoxime is found in high concentration in milk following intravenous ceftriaxone administration in acute mastitis in goat.  However, fibrosis is a major problem in chronic mastitis which reduces the bioavailability of the drug at the site of infection. Hence, the antibiotic treatment with concomitant herbal therapy may be a possible strategy.
The aqueous and ethanol extracts of Bauhinia variegata L. has been shown significant antioxidant activity in vitro. It has been reported that the bark is rich in the phenolic/flavonoid content.  Hence, the aim of the present work was to evaluate the potential of stem bark of B. variegata L. as adjunct therapy with intravenous ceftriaxone in chronic S. aureus mastitis in goat.
| Materials and Methods|| |
Ceftriaxone (analytical grade, purity ≥90%) and ceftizoxime (analytical grade, purity ≥90%) were used as test drugs. The stem bark powder of B. variegata L. was used as an adjunct therapy.
Preparation of stem bark powder of Bauhinia
The tree (B. variegata L.) having white colored flowers was identified and authenticated by Department of Botany, University of Calcutta. Barks were shade dried and made into powder.
Isolation and identification of Staphylococcus aureus
Staphylococcus aureus (strain J638) was isolated from the mastitic milk sample from a Jamunapari goat in mannitol salt agar (MSA, HiMedia, India), which was confirmed by colony characteristics in MSA, Gram-staining and standard biochemical tests such as catalase, oxidase, indole, Methyl Red, Voges-Proskauer, urease, carbohydrate fermentation, and coagulase test. 
Antibiotic sensitivity test
The coagulase positive S. aureus isolate (J638) was tested for its sensitivity to ceftriaxone, ceftizoxime, and aqueous solution of B. variegata L. stem bark powder by the disc diffusion method. 
Inclusion and exclusion criteria
Before the start of the experiment, the animals were acclimatized for 7 days. Only apparently healthy lactating black Bengal goats aged 1-2 year weighing between 10 and 12 kg yielding about 170-200 ml milk/day and containing negligible quantity of S. aureus were included in this study. All the experimental procedures were conducted as per the guidelines of the Institutional Animal Ethical Committee (IAEC) (IAEC approval number: EC/94, dated June 24, 2011).
Induction and confirmation of chronic mastitis
Twelve clinically healthy lactating female black Bengal goats after 21 st day of parturition were inoculated with 2000 CFU of locally isolated coagulase positive S. aureus strain (J638). The inoculated animals were not milked out during the first 3 days postinoculation. The animals were closely observed for the development of any clinical sign for 4 weeks.
Confirmatory tests were conducted such as somatic cell count (SCC), California mastitis test (CMT), bromothymol blue (BTB) paper test and milk enzyme activity at every 5 days interval up to 30 days postinoculation (day 51 after parturition) with bacterial colony count at 0 th , 15 th , and 30 th day postinoculation (i.e. day 21, 36, and 51 after parturition). Histomorphological examination of the mammary gland was conducted on 30 th day postinoculation to confirm chronic mastitis.
Fixation of dose of the bark powder
Prepared stem bark powder was administered orally once daily at 6 g/kg body weight mixing with distilled water for consecutive 14 days. Biochemical parameters such as alanine transaminase (ALT), aspartate transaminase (AST) activity, plasma urea nitrogen (PUN), and creatinine (CRT) level were also monitored during this period. The dose level at 6 g/kg body weight did not alter the ALT, AST, PUN, and CRT level significantly. Hence, the dose rate was considered as nontoxic. ALT and AST activity, PUN level, plasma CRT level was determined as per the method described by Yatzidis (1960),  Wooton (1974)  and Varly (1975). 
Twelve experimentally induced chronic mastitic goats were randomly divided into two equal groups (Groups I and II). Group I mastitic goats were treated with intravenous ceftriaxone alone at 20 mg/kg body weight at 4 days interval, whereas Group II induced chronic mastitic goats were administered stem bark powder of B. variegata L. orally once daily at 6 g/kg body weight at 24 h interval consecutively for 7 days followed by 3 g/kg body weight (maintenance dose) orally once daily for next 7 days along with intravenous ceftriaxone at 20 mg/kg body weight at 4 days interval. The dosing of intravenous ceftriaxone was repeated when either the parent drug or its metabolite came to below the detectable level in milk of mastitic goats. Blood samples (2 ml) were collected at 0 (predosing), 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 h postdosing. Milk samples (2 ml) were collected from both the teats into the test tubes at 0 (predosing), 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, and 432 h postdosing. One milliliter of milk or plasma was taken for estimation of drug concentration by high performance liquid chromatography. Fresh milk sample (10 μL) was used for SCC and rest of the samples was stored at −20°C for enzymatic assay.
Somatic cell count
The SCC of the milk samples were conducted at 48 h interval postdosing by modified method of Petersson et al. (2011) for direct microscopic SCC with pyronin - Y-methyl green stain. 
Bacterial colony count, California mastitis test, bromothymol blue test and milk enzyme activity
The colony count of S. aureus was conducted as per the standard technique.  CMT and BTB test were conducted as per Chakrabarti (2007).  Milk alkaline phosphatase (ALP), lactoperoxidase (LPO) activity and reduced glutathione (rGSH) level were estimated by the method described by Bernt, 1974,  Makinen and Tenovuo, 1982  and Pecker, 1994. 
High performance liquid chromatography analysis of plasma or milk
The extraction of the drugs (ceftriaxone and/or ceftizoxime) was done according to the modified method of Sar et al., 2011.  The mobile phase was prepared according to the method of United States Pharmacopoeia.
Mammary gland tissues were collected from left and right half of the udder of chronic mastitis induced animals on 30 days postinoculation and after completion of treatment period from Group II animals with biopsy needle and fixed in 10% formalin.  The fixed tissues were further processed  and stained with Van-Gieson's stain for collagen fibers. 
The data were analyzed by paired t-test and t-test of independent sample assuming equal variance using SPSS 10.0 (Manufactured by SPSS Inc., USA).
| Results|| |
Confirmation of chronic mastitis
Toward the end of the 2 nd week, the milk became watery and negligible amount of milk yield from left teat was recorded in animals of both Groups I and II. However, the right half of the udder in both groups yielded reduced amount of milk [Table 1]. By 30 th day postinoculation, shrinkage of both halves of the udder with marked hardness of the gland was noticed in all the induced mastitic goats with increased SCC [Table 2] and bacterial colony count [Table 3]. Milk ALP activity was increased significantly, while LPO activity was reduced by 30 th day postinoculation. Histomorphological findings revealed profuse infiltration of polymorph nuclear cells along with excess proliferation of fibrous tissue [Figure 1]a and b in both half of the udder.
|Figure 1: (a) Mammary gland tissue (left half) after 30th day postinoculation revealing the presence of excess proliferation of fibrous tissue with disorganization of alveolar structures (×40), (b) mammary gland tissue (right half) after 30th day Postinoculation showing extensive fibrous tissue proliferation (×40), (c) mammary gland tissue (left half) after treatment exhibiting reduction of fibrous tissue (×40) in Group II, (d) mammary gland tissue (right half) after treatment revealing toward healthy glandular structures with little fibrous tissue surrounding (×40) in Group II|
Click here to view
|Table 1: Average milk yield (ml) before and after intracisternal inoculation of S. aureus and during/ after treatment in Group I animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval) and in Group II animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval with daily oral administration of stem bark powder of Bauhinia variegata L. for 14 days) |
Click here to view
|Table 2: SCC (mean±SD×103 cells/ml) before and after intracisternal inoculation of S. aureus and during/after treatment in Group I animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval) and in Group II animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval with daily oral administration of stem bark powder of Bauhinia variegata L. for 14 days) |
Click here to view
|Table 3: Bacterial colony count (mean±SD×1010 cfu/ml) before and after intracisternal inoculation of S. aureus and during/after treatment in Group I animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval) and in Group II animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval with daily oral administration of stem bark powder of Bauhinia variegata L. for 14 days) |
Click here to view
Antibiotic sensitivity test
The S. aureus (J638) isolate was found to be highly sensitive to ceftizoxime and intermediate sensitive to ceftriaxone. Whereas, aqueous extract of stem bark powder showed a zone of inhibition having a small diameter.
Plasma level of ceftriaxone and ceftizoxime
In Group II mastitic animals treated with repeated dose of intravenous ceftriaxone along with concurrent oral administration of stem bark powder, the concentration of the drug and its metabolite was increased, and their persistence also found to be prolonged [Table 4].
|Table 4: Mean concentration (μg/ml) of (a) ceftriaxone and (b) ceftizoxime in Group I animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval) and in Group II animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval with daily oral administration of stem bark powder of Bauhinia variegata L. for 14 days) in plasma |
Click here to view
Milk level of ceftriaxone and ceftizoxime
The drug concentration could not be determined in the left half of Group I animals due to scanty milk secretion at all-time intervals. In the right half of the udder, ceftriaxone could not be detected in milk even after the second dose. Instead, only its metabolite that is, ceftizoxime was detected in milk at 24 h postdosing [Table 5]. Following the second dose at 96 h, ceftizoxime was again detected in milk from 120 h and was available up to 216 h, whereas in Group II animals, along with ceftizoxime, ceftriaxone was also detected in milk of both right and left half of the udder and persisted for a longer time [Table 5].
|Table 5: Mean concentration (μg/ml) of (a) ceftriaxone and (b) ceftizoxime in Group I animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval) and in Group II animals (treated with intravenous ceftriaxone at 20 mg/kg at 4 days interval with daily oral administration of stem bark powder of Bauhinia variegata L. for 14 days) in milk |
Click here to view
Milk somatic cell count
There was no significant improvement in mean SCC in Group I mastitic animals treated with ceftriaxone alone [Table 2]. Whereas in Group II animals, average SCC was found to be decreased in left and right half from day 57 to 59, respectively [Table 2].
Bacterial colony count
In Groups I and II animals, the mean bacterial colony count of both half of the udder was found to be decreased and in Group II no single colony was detected in the milk samples from 96 h postdosing in either half of the udder [Table 3].
Milk enzyme activity
The mean ALP activity, LPO activity and rGSH level were recorded to be in the range of 5872.35 ± 457.09-6438.14 ± 349.81 nmole ρNP/h/ml, 27942.92 ± 5426.64-39745.76 ± 2607.03 μmole/min/L and 344.40 ± 20.82-362.60 ± 7.84 ηmole GSH/ml, respectively. By 30 th day postinoculation (day 51 after parturition) ALP activity and rGSH level were increased to 18778.67 ± 841.70-20628.99 ± 1958.53 nmole ρNP/h/ml and 394.30 ± 13.66-421.20 ± 18.99 ηmole GSH/ml, respectively, whereas LPO activity was decreased (18185.66 ± 1801.35-19886.57 ± 2846.29 μmole/min/L). In Group I animals treated with antibiotic alone, enzyme activity of the left half could not be determined due to almost cessation of milk while, in the right half, no significant change in ALP activity, LPO activity and rGSH level was noticed. In contrast, significant clinical improvement in animals of Group II has been evident from a significant reduction in ALP activity (8530.28 ± 957.97-9167.96 ± 532.05 nmole ρNP/h/ml) and remarkable increase in LPO activity (40711.06 ± 3935.50-40991.26 ± 3904.79 μmole/min/L) by 18 th day postdosing (day 71 after parturition).
California mastitis test
California mastitis test was found positive up to 144 h postdosing following first and second dose of ceftriaxone in Group I animals and in Group II animals, CMT was found negative in milk samples of 96 h postdosing and onwards from either half of the udder.
Clinical signs after treatment
The treated animals of Group I showed shrinkage of the left half with marked hardness and a negligible amount of milk production [Table 1]. However in Group II animals, following treatment milk secretion increased two-fold in both left and right half of the udder [Table 1].
Histomorphological study following completion of treatment revealed reduction of the fibrous tissue in the left half of the udder [Figure 1]c whereas in the right side, more amount of columnar epithelial cells with multiple alveoli were found showing progress toward normal glandular structure of the mammary gland [Figure 1]d in Group II.
| Discussion|| |
In this study, SCC varied between 554.00 ± 45.93 and 772.17 ± 72.55 × 10 3 cells/mL in milk of healthy goats prior to challenge, which was increased significantly by 30 th day postinoculation of S. aureus [Table 2]. These findings corroborated with the findings of Pettersen (1981)  and Kozacinski et al. (2002).  Bacterial colony count confirmed increased number of S. aureus on 30 th day postchallenge [Table 3]. Declined milk yield and significant increase (P < 0.05) in ALP activity in milk from both half of the udder in all the groups inoculated with S. aureus along with decrease in LPO activity is an indication of mastitis.  Histomorphological examination exhibited excess proliferation of fibrous tissue in both half of the udder [Figure 1]a and b indicating chronic mastitis.
The concentration of ceftriaxone/ceftizoxime in plasma was significantly higher (P < 0.05) in the Group II animals compared to the Group I animals which indicated bio-enhancing effect of B. variegata Linn. Both ceftriaxone and its metabolite were detected in milk samples of Group II animals for a longer time and with a considerably higher concentration, which substantiated the possible bio-enhancing action of the bark powder.
Significant decrease in SCC from 96 h postdosing in the left half and from 144 h postdosing in the right half in Group II animals during treatment compared to SCC in chronic mastitic condition along with a significant reduction in the bacterial colony count indicated both antiinflammatory and enhanced antibacterial activity of intravenous ceftriaxone in presence of stem bark powder of B. variegata L. It was further supported by the results of CMT.
In all animals of both Groups I and II, postchallenge milk ALP activity was increased significantly (P < 0.05), which suggested substantial tissue damage in mammary gland.  Synthesis of LPO was interfered in these goats due to substantial tissue damage, which was also evident from significantly reduced LPO activity in mastitic condition. A significant increase in LPO activity with a marked reduction in milk ALP activity in Group II animals suggested possible recovery of the animals from chronic mastitis. Hence, it can be concluded that stem bark powder of B. variegata L. as an adjunct therapy potentiated the antibacterial effect of intravenous ceftriaxone. The milk production was also increased in Group II animals following treatment compared to Group I animals, which received antibiotic only.
Histomorphological evaluation exhibited marked a reduction of the fibrous tissue in the left half and more number of active columnar epithelial cells in the right half of the udder in Group II animals, which indicated antifibrotic activity of B. variegata L.
| Conclusion|| |
Hence, bark powder of B. variegata L., having bioenhancing, antibacterial, antiinflammatory, antioxidant and antifibrotic properties might be an effective adjunct therapy with antibiotic treatment in chronic mastitis.
| Acknowledgment|| |
We acknowledge Dr. Katherine Petersson, Assistant Professor, University of Rhode Island, Department Fisheries, Animal and Veterinary Science, Kingston, USA for his generous assistance during this study.
| References|| |
|1.||Fox LK, Gay JM. Proceedings of the Coliform Mastitis Symposium. Veterinary Learning Systems. Trenton, New Jersey; 1993. p. 56. |
|2.||Sawant AA, Sordillo LM, Jayarao BM. A survey on antibiotic usage in dairy herds in Pennsylvania. J Dairy Sci 2005;88:2991-9. |
|3.||Sar TK, Mandal TK, Das SK, Chakraborty AK, Bhattacharyya A. Pharmacokinetics of ceftriaxone in healthy and mastitic goats with special reference to its interaction with polyherbaldrug (Fibrosin ® ). Int J Appl Res Vet Med 2006;4:142-54. |
|4.||Rajani GP, Ashok P. In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn. Indian J Pharmacol 2009;41:227-32. |
|5.||Sharma N, Bhardwaj R, Kumar S, Kaur S. Evaluation of Bauhinia variegata L. bark fractions for in vitro antioxidant potential and protective effect against H 2 O 2 induced oxidative damage to pBR322 DNA. Afr J Pharm Pharmacol 2011;5:1494-500. |
|6.||Quinn PJ, Carter ME, Markey BK, Carter GR. Clinical Veterinary Microbiology. London, UK: Wolf Publishing; 1994. p. 21-66. |
|7.||Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-6. |
|8.||Yatzidis H. Measurement of transaminases in serum. Nature 1960;186:79-80. |
|9.||Wooton ID. Estimation of protein by biuret method. In: Micro Analysis in Medical Biochemistry. 5 th ed. Edinburg and London: Churchill Livingstone; 1974. p. 156-8. |
|10.||Varly H. Practical Clinical Biochemistry. New Delhi: Arnold-Heinemann Publishers (India) Pvt. Ltd.; 1975. |
|11.||Petersson KH, Connor LA, Petersson-Wolfe CS, Rego KA. Evaluation of confirmatory stains used for direct microscopic somatic cell counting of sheep milk. J Dairy Sci 2011;94:1908-12. |
|12.||Chakrabarti A. A Textbook of Preventive Veterinary Medicine. New Delhi, India: Kalyani Publishers; 2007. p. 479-80. |
|13.||Bernt E. Alkaline phosphatase assay. In: Bergmeter HU, editor. Methods of Enzymatic Analysis. 2 nd ed., Vol. 2. New York, USA: Academic Press; 1974. p. 868-70. |
|14.||Makinen KK, Tenovuo J. Observations on the use of guaiacol and 2,2'-azino-di (3-ethylbenzthiazoline-6-sulfonic acid) as peroxidase substrates. Anal Biochem 1982;126:100-8. |
|15.||Pecker L. Methods of Enzymology. San Diego, California, USA: Academic Press; 1994. |
|16.||Sar TK, Patra PH, Dash JR, Mandal TK. Pharmacokinetic interaction of intramammary ceftriaxone and oral polyherbal drug (Fibrosin ® ) in goats. Drug Metabol Drug Interact 2011;26:191-6. |
|17.||Bancroft JD, Stevens A. Theory and Practice of Histological Techniques. 4 th ed. Edinburgh: Churchil Livingstone; 1996. |
|18.||Luna LG. The Manual of Histologic Staining Techniques. 3 rd ed. New York: Armed Forces Institute of Pathology, McGraw Hill Co.; 1968. p. 32-46. |
|19.||Mallory FB. Pathological Technique. New York: Hafner Publishing Co; 1961. p. 152. |
|20.||Pettersen KE. Cell content in goat's milk. Acta Vet Scand 1981;22:226-37. |
|21.||Kozacinski L, Hadziosmanovic M, Majic T, Karadjole I, Cvrtila Z. Relationships between the results of mastitis tests, somatic cell counts and the detection of mastitis in goat's milk. Tierarztliche Umschau 2002;57:255-60. |
|22.||Sar TK, Samanta I, Patra PH, Mandal TK. Effect of combined therapy of intravenous ceftriaxone and oral polyherbal drug on milk enzyme activity in healthy and mastitic goats. Appl Biol Res 2012;14:95-9. |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]